Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma

Jorge J. Castillo, Thomas Guerrero-Garcia, Francesco Baldini, Emmanuelle Tchernonog, Guillaume Cartron, Slavisa Ninkovic, Kate Cwynarski, Daan Dierickx, Thomas Tousseyn, Frederick Lansigan, Yevgeny Linnik, Renzo Mogollon, Jose Tomás Navarro, Adam J. Olszewski, John L. Reagan, Pasquale Fedele, Michael Gilbertson, George Grigoriadis, Michele Bibas

Research output: Contribution to journalLetterOtherpeer-review

8 Citations (Scopus)
Original languageEnglish
Pages (from-to)679-682
Number of pages4
JournalBritish Journal of Haematology
Volume184
Issue number4
DOIs
Publication statusPublished - 1 Feb 2019

Keywords

  • Bortezomib
  • Chemotherapy
  • Plasmablastic lymphoma
  • Survival

Cite this

Castillo, J. J., Guerrero-Garcia, T., Baldini, F., Tchernonog, E., Cartron, G., Ninkovic, S., ... Bibas, M. (2019). Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. British Journal of Haematology, 184(4), 679-682. https://doi.org/10.1111/bjh.15156